Truist upgrades Sabra Health Care REIT to Buy, keeps $22 target
Truist Securities analyst Michael Lewis upgraded Sabra Health Care REIT from Hold to Buy, maintaining a $22 price target. The report signals increased confidence in the stock's ability to outperform.
*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Michael Lewis has upgraded Sabra Health Care REIT from Hold to Buy while maintaining a price target of $22. This rating change signals increased confidence in the healthcare real estate investment trust's potential to outperform the market. The upgrade and target price were detailed in a recent report, offering investors a revised outlook on the stock's trajectory.
Analyst Details
The coverage update comes from Michael Lewis, an analyst at Truist Securities. The shift from Hold to Buy suggests that the stock is now expected to deliver returns superior to the broader market or the analyst's coverage universe. This adjustment reflects a reassessment of the company's fundamentals or market position.
Price Target
The price target maintained by Truist Securities stands at $22. This figure represents the analyst's projection of where the stock price is headed within a specific timeframe, providing investors with a concrete benchmark for valuation. The decision to keep the target steady despite the rating upgrade indicates that the previous price goal remains appropriate under the new bullish thesis.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Rating | Hold |
| Price Target | $22 |
| Coverage Updated By | Michael Lewis (Truist Securities) |
What specific fundamental changes or market conditions prompted the upgrade from Hold to Buy?
How does Sabra Health Care REIT plan to navigate potential interest rate fluctuations given its REIT status?
What are the expected growth drivers for Sabra Health Care REIT in the healthcare real estate sector?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
